Iheezo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792271 SINTETICA SA Topical formulations of chloroprocaine and methods of using same
Sep, 2038

(14 years from now)

Iheezo is owned by Sintetica Sa.

Iheezo contains Chloroprocaine Hydrochloride.

Iheezo has a total of 1 drug patent out of which 0 drug patents have expired.

Iheezo was authorised for market use on 27 September, 2022.

Iheezo is available in gel;ophthalmic dosage forms.

Iheezo can be used as method of inducing ocular anesthesia.

The generics of Iheezo are possible to be released after 15 September, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Sep 27, 2025

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 27 September, 2022

Treatment: Method of inducing ocular anesthesia


More Information on Dosage

IHEEZO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic